Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin America are expected to impede growth of the global dermatophytic onychomycosis therapeutics market.
Dermatophytic Onychomycosis Therapeutics (DOT) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Dermatophytic Onychomycosis Therapeutics (DOT) market is projected to reach US$ 6835.3 million in 2034, increasing from US$ 3394.3 million in 2022, with the CAGR of 10.3% during the period of 2024 to 2034. Demand from Hospitals and Dermatology And Podiatry Clinics are the major drivers for the industry.
The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again sub-divided into prescription (Rx) and over-the-counter (OTC) sub segments. The nail paint segment is expected to contribute a maximum share to the global dermatophytic onychomycosis therapeutics market. By treatment, the market is segmented into topical and oral therapy. Among these, the topical segment is anticipated to be dominant throughout the forecast period and projected to account for about 70% share of the total global dermatophytic onychomycosis market revenue by 2025.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dermatophytic Onychomycosis Therapeutics (DOT) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Galderma
Bausch Health
Novartis
Pfizer
Janssen
Segment by Type
Topical
Oral Therapy
Hospitals
Dermatology And Podiatry Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Dermatophytic Onychomycosis Therapeutics (DOT) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Dermatophytic Onychomycosis Therapeutics (DOT) introduction, etc. Dermatophytic Onychomycosis Therapeutics (DOT) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Dermatophytic Onychomycosis Therapeutics (DOT) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Dermatophytic Onychomycosis Therapeutics (DOT) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Dermatophytic Onychomycosis Therapeutics (DOT) market is projected to reach US$ 6835.3 million in 2034, increasing from US$ 3394.3 million in 2022, with the CAGR of 10.3% during the period of 2024 to 2034. Demand from Hospitals and Dermatology And Podiatry Clinics are the major drivers for the industry.
The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again sub-divided into prescription (Rx) and over-the-counter (OTC) sub segments. The nail paint segment is expected to contribute a maximum share to the global dermatophytic onychomycosis therapeutics market. By treatment, the market is segmented into topical and oral therapy. Among these, the topical segment is anticipated to be dominant throughout the forecast period and projected to account for about 70% share of the total global dermatophytic onychomycosis market revenue by 2025.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dermatophytic Onychomycosis Therapeutics (DOT) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Galderma
Bausch Health
Novartis
Pfizer
Janssen
Segment by Type
Topical
Oral Therapy
Segment by Application
Hospitals
Dermatology And Podiatry Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Dermatophytic Onychomycosis Therapeutics (DOT) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Dermatophytic Onychomycosis Therapeutics (DOT) introduction, etc. Dermatophytic Onychomycosis Therapeutics (DOT) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Dermatophytic Onychomycosis Therapeutics (DOT) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices